Petrová, Lenka
XIII. Výročný kongres Medzinárodnej spoločnosti pre farmakoekonomiku a výskum výsledkov. Toronto, 3.-7.V.2008. Časť 2., Diabetológia, kardiológia, neurológia / Lenka Petrová, Veronika Dubajová, Viliam Foltán. -- Voľný preklad z kongresových materiálov - Obsahuje tiež: Cost-effectiveness of drug therapy for diabetes mellitus - a systematic review / Y. J. Zhang - Cost and effectiveness of insulin vs rosiglitazone in type II diabetes after metformin monotherapy failure / J. Skoupá - Comparison of resource utilization (RU) and cost in drug naive type 2 diabetes (T2D) patients treated with rosiglitazone (RSG) verzus sulfonylurea (SU) monotherapy / A. Gosselin - Hagedorn in type 1 diabetes patients in the Czech setting - data from PREDICTIVE™ study / J. P. Clegg - Cost-effectiveness of insulin detemir compared to NPH insulin for type 2 diabetes mellitus (T2DM) in the Canadian payer setting: modeling analysis using an observational study / M. E. Minshall - Clinical and economic characteristics of patienta with diabetic neuropathy / Y. Zhao - Medical care of patients with diabetic neuropathy: impact of type 1 diabetes and presence of other diabetes-related complications / Y. Zhao - Cost-effectiveness of insulin detemir versus NPH insulin for type 1 diabetes patients treated with basal-bolus therapy in Portugal / C. Silva - A modelled cost-effectiveness analysis of switching patients with poorly controlled type 2 diabetes to insulin detemir from oral antidiabetics or NPH in the Austrian setting; data from the PREDICTIVE study / L. Stechemesser - Exenatide utilization and effectiveness in a health plan population / B. Schroeder - Canadian cost utility analysis comparing exenatide versus insulin glargine in patients with type 2 diabetes / D. Coyle - Lost productivity associated with type 1 and type 2 diabetes in a commercially insured population / E. Durden - Systematic review of adherence, compliance and Quality of life in type 2 diabets patients / J. B. Kumar - Comparison of healthcare utilization and cost in type 2 diabetes patients initiating analog and human insulins / J. Margolis - Likelihood and cost of adverse events in atrial fibrillation are associated with choice of acute conversion therapy / M. Belz - Economic evaluation of atosiban versus beta-mimetics in the treatment of preterm labour in Germany / J. Wex - Evaluation of resistant hypertension in a usual-care setting / C. McAdam-Marx - Blood pressure success zone longitudinal study of succes (BPSZ - BLISS): an observational, multicenter study of the impact of the BPSZ educational program on blood pressure control, perzistence, compliance and treatment satisfaction. Enrollment metrics and baseline cohort characteristics / K. A. Payne l - A modified RxRisk-V comorbidity index predicts adherence with lipid lowering therapy (LLT) / S. R. Ghate - Assessment and quantification of the benefit risk ratio of rosuvastatin and atorvastatin from a meta-analysis of head-to-head randomised controlled trials / J. Wlodarczyk - The cost and effectiveness of adherence-improving interventions for lipid-lowering and antihypertensive drugs / R. H. Chapman - The cost-utility of aliskiren in the treatment of mild to moderate hypertension. A Canadian healthcare system perspective / A. Lee - A flexible tool to estimate medical care costs for study events in cardiovascular endpoints trials / D. Thompson - The impact of targeted member education on choice of preferred statin therapy after a formulary change / E. Cox - Begian budget impact analyses of aliskiren (Tekturna®/Rasilez®) in hypertension / P. Lecomte - The cost-effectiveness of aliskiren as add on to losartan and optimal antihypertensive therapy in patients with type 2 diabetes, hypertension and nephropathy in the UK setting / J. L. Palmer - Patient adherence to cholesterol treatment (PACT): Canadian physician and patient perspectives / B. Beamer - Clinical determinants of satisfaction and health related quality of life in patients with cardiac disease and dyslipidemia / A. D. Raju - Bosentan is a cost-effective treatment for UK patients with pulmonary arterial hypertension of WHO class III / M. Stevenson - Clopidogrel is cost-effective compared with aspirin in UK patients with a myocardial infarction WHO subsequently suatain an ischaemic stroke or diagnosis of peripheral arterial disease / M. Stevenson - Impact of adoption of new antihypertensive drugs on the healthcare utilization in hypertensive patients / A. Ganguli - Impact of prescription copay on adherence to renin-angiotensin system agents in heart failure patients / Xiaolan Ye - Physical and patient-reported outcomes in multiple sclerosis / S. Kirzinger - Migraine suffers show significant health care utilization and expenditures / R. G. Iyer - Modeling the impact of a fixed-dose combination of sumatriptan and naproxen sodium on triptan consumption in a US managed care population / T. W. Smith - Severity of illness among persons with multiple sclerosis: an analysis of cost quintiles / N. L. Kleinman - Prevalence and costs of comorbidities among persons with and without multiple sclerosis: an analysis of the AHRQ major and specific diagnostic categories / R. A. Brook - Relationship between adherence to multiple sclerosis medications and total health care costs / N. G. Khandelwal - Exploring the impact of different dispensing systems on medication compliance and persistence in multiple sclerosis patients using pharmacy claims data / J. Tang - Cost of disability and medically-related absenteeism among employees with multiple sclerosis / H. G. Birnbaum - Comparison of compliance and persistence with immunomodulating agents for multiple sclerosis in a commercially insured population / T. Shea - Association between change in overall quality of life (QoL), disease level and functional status since natalizumab initiation / K. Rajagopalan - Switching to high-dose, high-frequency interferons or natalizumab in patients with multiple sclerosis: a cost-effectiveness analysis / C. Fischer - Medical costs associated with treatment change in multiple sclerosis / B. L. Nordstrom - Impact of non-adherence to antiepileptic drugs on morbidity: results from a medicaid population / J. R. Weiner - The concentration and persistence of health care expenditures and prescription drug expenditures in patients with Alzheimer's disease / Pei-Jung Lin

In Farmakoekonomika a lieková politika : oficiálny časopis Slovenskej spoločnosti pre farmakoekonomiku. -- Nové Mesto nad Váhom : TISING, 2008. -- s. 2-64. -- ISSN 1336-7021. -- Roč. 4, č. 3 (2008), s. 27-28 a 30-53

1. International Society for Pharmacoeconomics and Outcomes Research. Annual international meeting (13. : 2008 : Toronto, Kanada) 2. farmakoekonomika 3. náklady a analýza nákladov 4. diabetes mellitus - ekonomika 5. komplikácie diabetu - ekonomika 6. choroby kardiovaskulárne - ekonomika 7. choroby nervového systému - ekonomika 8. farmakoterapia - ekonomika

I. Dubajová, Veronika
II. Foltán, Viliam, 1946-
III. Farmakoekonomika a lieková politika : oficiálny časopis Slovenskej spoločnosti pre farmakoekonomiku. -- Roč. 4, č. 3 (2008), s. 27-28 a 30-53